Verona Pharma plc
VRNA
$63.32
-$2.94-4.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 238.22% | 201.13% | 163.58% | 294.20% | 113.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 225.30% | 201.43% | 168.83% | 467.91% | 33.83% |
| Operating Income | 61.23% | 1.53% | -134.99% | -467.91% | -33.83% |
| Income Before Tax | 33.87% | -80.16% | -191.69% | -721.71% | -51.12% |
| Income Tax Expenses | -131.70% | 15,705.66% | 468.18% | 227.10% | 335.84% |
| Earnings from Continuing Operations | 36.73% | -139.36% | -192.52% | -704.30% | -54.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.73% | -139.36% | -192.52% | -704.30% | -54.06% |
| EBIT | 61.23% | 1.53% | -134.99% | -467.91% | -33.83% |
| EBITDA | 61.97% | 1.84% | -135.58% | -473.21% | -33.56% |
| EPS Basic | 39.86% | -131.69% | -186.37% | -687.57% | -48.31% |
| Normalized Basic EPS | 38.68% | -74.39% | -185.61% | -661.79% | -45.46% |
| EPS Diluted | 39.86% | -110.11% | -186.37% | -687.57% | -48.31% |
| Normalized Diluted EPS | 38.68% | -74.39% | -185.61% | -661.79% | -45.46% |
| Average Basic Shares Outstanding | 5.22% | 3.29% | 2.15% | 2.17% | 3.90% |
| Average Diluted Shares Outstanding | 5.22% | 3.29% | 2.15% | 2.17% | 3.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |